All Articles In 'Prescription Drug Benefits'

Medicare Data Book for 2010: MedPAC Data on Medicare Spending, Enrollment, Providers, Health Plans, Drug Plans, and More

Medicare Data Book for 2010: MedPAC Data on Medicare Spending, Enrollment, Providers, Health Plans, Drug Plans, and More

MedPAC released its Medicare Data Book for 2010, with a wide range of useful information on Medicare spending, utilization, beneficiaries, providers, health plans, drug plans, access, and quality. The format is reader-friendly charts and tables with [...]

Impact of Health Reform on Medicare Advantage, Medicare Drug Plans, and Part D Drug Benefit

Impact of Health Reform on Medicare Advantage, Medicare Drug Plans, and Part D Drug Benefit

Medicare Advantage plans and Medicare Part D prescription drug plans face an extraordinary array of changes as a result of the Patient Protection and Affordable Care Act (PPACA) and the Health Care and Education Reconciliation Act [...]

American Health and Drug Benefits: March – April 2010 Issue

American Health and Drug Benefits: March – April 2010 Issue

The latest issue of the journal American Health & Drug Benefits includes a valuable mix of studies and articles on economic, regulatory, and clinical issues of particular interest to payors, purchasers, and policymakers. Obesity: Effective Treatment [...]

Wellness-Based Healthcare: Prevention, Intervention, and Innovation for Chronic Diseases

Wellness-Based Healthcare: Prevention, Intervention, and Innovation for Chronic Diseases

Creating a wellness-based healthcare system is the focus on a new series of articles published by American Health and Drug Benefits, a peer reviewed journal. They cover a wide spectrum of topics on how to build [...]

Medicare Payment Policy:  MedPAC Recommendations to Congress for 2011

Medicare Payment Policy: MedPAC Recommendations to Congress for 2011

The Medicare Payment Advisory Commission (MedPAC) has released its Medicare payment recommendations to Congress for 2011. In addition to specific recommendations for payment updates for fee-for-service providers and Medicare Advantage plans, MedPAC’s report includes interesting information [...]

American Health and Drug Benefits: January – February 2010 Issue

American Health and Drug Benefits: January – February 2010 Issue

Here are articles from the latest issue of American Health & Drug Benefits. AHDB is a peer-reviewed journal for 30,000 decision makers in health plans, PBMs, Medicare, Medicaid, and the pharma and biotech industries: Orphan Drug [...]

National Health Expenditures for 2009-2019:  CMS Actuary Projections

National Health Expenditures for 2009-2019: CMS Actuary Projections

The Centers for Medicare and Medicaid Services’ Office of the Actuary (CMS/OACT) has released its projections of U.S. health care spending for the ten years 2010 through 2019, with premliminary estimates of 2009 health spending. The [...]

American Health and Drug Benefits: September – October 2009 Issue

American Health and Drug Benefits: September – October 2009 Issue

Here are articles from the latest issue of American Health & Drug Benefits. AHDB is a peer-reviewed journal for 30,000 decision makers in health plans, PBMs, Medicare, Medicaid, and the pharma and biotech industries: Predictive and [...]

Pharmaceutical Research & Development in a Value-Based Healthcare System

Pharmaceutical Research & Development in a Value-Based Healthcare System

At the last annual meeting of the Academy of Managed Care Pharmacy, several of us spoke on pharmaceutical research and development in the quickly emerging value-driven healthcare system. Topics focused on the impact of value-based benefit [...]

Comparative Effectiveness Research: AHRQ Plan for $300 million in New Research, Patient Registries, Infrastructure, and Dissemination

Comparative Effectiveness Research: AHRQ Plan for $300 million in New Research, Patient Registries, Infrastructure, and Dissemination

The HHS Agency for Healthcare Research and Quality (AHRQ) has announced plans for spending its $300 million share of the $1.1 billion Congress appropriated for comparative effectiveness research (CER) under the American Recovery and Reinvestment Act [...]